ACTIVE HALF-LIFE
2-4 days
CLASSIFICATION
Non-steroidal Aromatase Inhibitor
DOSAGE
2.5-5 mg/day
ACNE
None
WATER RETENTION
None
HBR
None
HEPATOTOXICITY
None
AROMATIZATION
None
MANUFACTURER
Deus Medical
LAB TEST
Refer to Document
WAREHOUSE
EU Warehouse 2
SUBSTANCE
Letrozole
Discover the power of FEMAMED 2.5 (Letrozole), a leading non-steroidal aromatase inhibitor designed for effective hormonal treatment of breast cancer. With an active half-life of 2-4 days, this medication plays a crucial role in managing estrogen levels in the body, which is vital since the growth of many breast cancers is driven by estrogens, the key female sex hormones.
By inhibiting the aromatase enzyme responsible for estrogen production, FEMAMED 2.5 significantly reduces estrogen levels, helping to slow the progression of estrogen-dependent breast cancer. Trust in Deus Medical's commitment to quality with this specialized treatment, available now from our EU warehouse. For detailed lab results, please refer to the accompanying document.